Kentaro Tanaka

9.5k total citations · 1 hit paper
307 papers, 6.7k citations indexed

About

Kentaro Tanaka is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Kentaro Tanaka has authored 307 papers receiving a total of 6.7k indexed citations (citations by other indexed papers that have themselves been cited), including 120 papers in Pulmonary and Respiratory Medicine, 92 papers in Oncology and 45 papers in Molecular Biology. Recurrent topics in Kentaro Tanaka's work include Lung Cancer Treatments and Mutations (48 papers), Cancer Immunotherapy and Biomarkers (26 papers) and Lung Cancer Research Studies (23 papers). Kentaro Tanaka is often cited by papers focused on Lung Cancer Treatments and Mutations (48 papers), Cancer Immunotherapy and Biomarkers (26 papers) and Lung Cancer Research Studies (23 papers). Kentaro Tanaka collaborates with scholars based in Japan, United States and China. Kentaro Tanaka's co-authors include Masato Kubo, Yoichi Nakanishi, Akihiko Yoshimura, Seizo Sadoshima, Kazumi Makishima, Katsuo Sueishi, Kazunari Oka, Makoto Hashizume, Isamu Okamoto and Dinis Pedro Calado and has published in prestigious journals such as Science, Proceedings of the National Academy of Sciences and Circulation.

In The Last Decade

Kentaro Tanaka

286 papers receiving 6.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Foxp3-Dependent MicroRNA155 Confers Competitive Fitness to Regulatory T Cells by Targeting SOCS1 Protein

2009 665 citations Kentaro Tanaka et al. profile →

Peers

Countries citing papers authored by Kentaro Tanaka

Since Specialization

Citations

This map shows the geographic impact of Kentaro Tanaka's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kentaro Tanaka with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kentaro Tanaka more than expected).

Fields of papers citing papers by Kentaro Tanaka

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kentaro Tanaka. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kentaro Tanaka. The network helps show where Kentaro Tanaka may publish in the future.

Co-authorship network of co-authors of Kentaro Tanaka

This figure shows the co-authorship network connecting the top 25 collaborators of Kentaro Tanaka. A scholar is included among the top collaborators of Kentaro Tanaka based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kentaro Tanaka. Kentaro Tanaka is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	TP53 gain-of-function mutations promote osimertinib resistance via TNF-α–NF-κB signaling in EGFR-mutated lung cancer 2024 ·npj Precision Oncology ·(unknown), Eiji Iwama, (unknown), (unknown), Yasuto Yoneshima, Kentaro Tanaka, Isamu Okamoto	13
2	Topological radiogenomics based on persistent lifetime images for identification of epidermal growth factor receptor mutation in patients with non-small cell lung tumors 2024 ·Computers in Biology and Medicine ·(unknown), Hidetaka Arimura, (unknown), Kentaro Tanaka, Hidetake Yabuuchi, (unknown), Chong Kin Liam, Chee-Shee Chai, Kwan Hoong Ng	0
3	Therapeutic effects of an ALK inhibitor, brigatinib, on lung large cell neuroendocrine carcinoma with EML4-ALK fusion 2024 ·Respiratory Investigation ·(unknown), (unknown), (unknown), (unknown), Hajime Yonezawa, Kazuhiro Tabata, Naohiko Seki, (unknown), Kentaro Tanaka, Hiromasa Inoue	2
4	Long-term efficacy of mepolizumab on eosinophilic granulomatosis with polyangiitis: a retrospective study 2024 ·Takahiro Matsuyama, (unknown), (unknown), (unknown), (unknown), Hiroko Uchida, Shunsuke Yasuda, (unknown), Koichi Takagi, Takayuki Suetsugu, (unknown), Kentaro Machida, Keiko Mizuno, Kentaro Tanaka, Hiromasa Inoue	1
5	Three-dimensional topological radiogenomics of epidermal growth factor receptor Del19 and L858R mutation subtypes on computed tomography images of lung cancer patients 2023 ·Computer Methods and Programs in Biomedicine ·Kenta Ninomiya, Hidetaka Arimura, Kentaro Tanaka, Wai Yee Chan, (unknown), Shinichi Mizuno, (unknown), (unknown), Chong Kin Liam, Chee-Shee Chai, Kwan Hoong Ng	7
6	512MO FLAURA2: Safety and CNS outcomes of first-line (1L) osimertinib (osi) ± chemotherapy (CTx) in EGFRm advanced NSCLC 2023 ·Annals of Oncology ·David Planchard, Pasi A. Jänne, Ying Cheng, Chee Khoon Lee, К. К. Лактионов, (unknown), Yan Yu, Terufumi Kato, Lingxiang Jiang, (unknown), Sarayut Lucien Geater, (unknown), (unknown), Libor Havel, Frances A. Shepherd, Kentaro Tanaka, Dana Ghiorghiu, Edgar Monterroso, (unknown), James Chih‐Hsin Yang	0
7	Role of Regional Core Centers for Liver Disease Management in the Continuity of Activities of Hepatitis Medical Care Coordinators 2023 ·Kanzo ·Hiroko Setoyama, (unknown), (unknown), Yoko Yoshimaru, (unknown), (unknown), Kentaro Tanaka, (unknown), Takayuki Tokunaga, Etsuko Iio, Katsuya Nagaoka, Takehisa Watanabe, Yuichiro Eguchi, Yasuhito Tanaka	1
8	MicroRNA‐326 negatively regulates CD155 expression in lung adenocarcinoma 2023 ·Cancer Science ·(unknown), Yasuto Yoneshima, Koji Okamura, Toyoshi Yanagihara, Mikiko Hashisako, Takeshi Iwasaki, Naoki Haratake, (unknown), Keiichi Ota, Eiji Iwama, Tomoyoshi Takenaka, Kentaro Tanaka, Tomoharu Yoshizumi, Yoshinao Oda, Isamu Okamoto	4
9	Impact of increased plasma levels of calreticulin on prognosis of patients with advanced lung cancer undergoing combination treatment of chemotherapy and immune checkpoint inhibitors 2023 ·Lung Cancer ·(unknown), Hiroyuki Inoue, Yoshimasa Shiraishi, (unknown), (unknown), Hiroyuki Ando, (unknown), (unknown), Hiroaki Ogata, Koji Okamura, Shinichi Kimura, Tomohiro Ogawa, Keiichi Ota, Yasuto Yoneshima, Kentaro Tanaka, Naoki Hamada, Isamu Okamoto, Eiji Iwama	8
10	Evaluation of appropriate conditions for Oncomine DxTT testing of FFPE specimens for driver gene alterations in non–small cell lung cancer 2023 ·Thoracic Cancer ·Eiji Iwama, Hidetaka Yamamoto, (unknown), Kayo Ijichi, (unknown), (unknown), Yasuto Yoneshima, Kentaro Tanaka, Yoshinao Oda, Isamu Okamoto	4
11	A multicenter, open‐label, single‐arm study of anamorelin (ONO‐7643) in patients with cancer cachexia and low body mass index 2022 ·Cancer ·Tateaki Naito, Junji Uchino, Toru Kojima, (unknown), Koichi Minato, Kentaro Tanaka, Takuro Mizukami, Shinji Atagi, Takashi Higashiguchi, Kei Muro, Koichi Takayama, Junji Furuse, (unknown), Toru Takiguchi, Kazuo Tamura	31
12	Immunostimulatory oncolytic activity of coxsackievirus A11 in human malignant pleural mesothelioma 2022 ·Cancer Science ·Koji Okamura, Hiroyuki Inoue, Kentaro Tanaka, (unknown), (unknown), Keiichi Ota, Yasuto Yoneshima, Eiji Iwama, Isamu Okamoto	5
13	A Multicenter, Randomized Phase III Study Comparing Platinum Combination Chemotherapy Plus Pembrolizumab With Platinum Combination Chemotherapy Plus Nivolumab and Ipilimumab for Treatment-Naive Advanced Non–Small Cell Lung Cancer Without Driver Gene Alterations: JCOG2007 (NIPPON Study) 2021 ·Clinical Lung Cancer ·Yoshimasa Shiraishi, Taiki Hakozaki, Shogo Nomura, Tomoko Kataoka, Kentaro Tanaka, Satoru Miura, Yuta Sekino, Masahiko Ando, Hidehito Horinouchi, Yuichiro Ohe, Isamu Okamoto	18
14	Quantification of HER family dimers by proximity ligation assay and its clinical evaluation in non–small cell lung cancer patients treated with osimertinib 2021 ·Lung Cancer ·Renpeng Liu, Keiichi Ota, Eiji Iwama, (unknown), Kentaro Tanaka, Hiroyuki Inoue, Tetsuzo Tagawa, Yoshinao Oda, Masaki Mori, Yoichi Nakanishi, (unknown)	4
15	Trim33 mediates the proinflammatory function of Th17 cells 2018 ·The Journal of Experimental Medicine ·Shinya Tanaka, Yu Jiang, Gustavo Martínez, Kentaro Tanaka, Xiaowei Yan, Tomohiro Kurosaki, Vesa Kaartinen, Xin‐Hua Feng, Qiang Tian, Xiaohu Wang, Chen Dong	45
16	Heparin-binding epidermal growth factor-like growth factor (HB-EGF) is involved in the pathogenesis of chronic allograft vasculopathy 2001 ·American Journal of Transplantation ·Takatomo Koshiba, (unknown), Tatsuaki Tsuruyama, (unknown), Kentaro Tanaka, Boudewijn Van Damme, Mark Waer, Jacques Pirenne	1
17	Ultrastructural study of the effects of tranexamic acid and urokinase on metastasis of Lewis lung carcinoma 1982 ·British Journal of Cancer ·(unknown), Hisataka Ogawa, Mitsuru Kinjo, Shin Kohga, Kentaro Tanaka	11
18	Thromboplastic and fibrinolytic activities of cultured human cancer cell lines 1979 ·British Journal of Cancer ·Mitsuru Kinjo, Kazunari Oka, Shotaro Naito, Shin Kohga, Kentaro Tanaka, Shoichi Oboshi, (unknown), K Yasumoto	72
19	Effect of urokinase on growth and metastases of rabbit V2 carcinoma. 1978 ·Munich Personal RePEc Archive (Ludwig Maximilian University of Munich) ·Yoshifumi Kodama, Kentaro Tanaka	8
20	Pathology of Disseminated Intravascular Coagulation(DIC):An Autopsy Survey (Proceedings of the 40 General Meeting of the Japan Hematological Society-2-) -- (Disseminated Intravascular Coagulation Syndrome(Symposium)) 1978 ·Kentaro Tanaka, Tsukasa Imamura, Teruo Watanabe	0

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact